Every material Form 8-K Curanex Pharmaceuticals Inc has filed with the SEC since May 14, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Curanex Pharmaceuticals disclosed two putative securities class actions in New York state court tied to its August 2025 initial public offering. The suits allege material misstatements and omissions in the IPO registration statement and prospectuses, including risks of stock-price manipulation and underwriter due diligence failures; the Company says it intends to defend them vigorously. The cases are at a preliminary stage and seek unspecified damages, so shareholders cannot yet assess the potential financial effect.
Morales action filed July 23, 2026 (Index No. 159271/2026), naming the Company and its underwriters among more than 20 other defendants
Lovett action filed September 14, 2026 (Index No. 655238/2026), also naming the Company's former CFO, directors and independent auditor
Both complaints seek unspecified compensatory damages and rescission or rescissory damages; neither asserts a fraud claim against the Company
Response deadlines: November 15, 2026 for Morales and December 11, 2026 for Lovett
Curanex Pharmaceuticals said Nasdaq has closed its bid price deficiency matter after the company's stock closed at or above $1.00 for 10 consecutive business days following a 1-for-20 reverse stock split effected August 20, 2026. The company remains listed on The Nasdaq Capital Market, which removes the immediate risk of delisting tied to the low share price.
Nasdaq notified the company on November 5, 2025 that its bid price had been below $1.00 for 30 consecutive business days.
The company effected a 1-for-20 reverse stock split on August 20, 2026.
On September 3, 2026, Nasdaq confirmed compliance based on closing bid prices from August 20 to September 2, 2026, and closed the matter.
Curanex Pharmaceuticals reported progress on its lead drug candidate, Phyto-N, in a first quarter 2026 business update furnished under Regulation FD. The company completed a GMP pilot-scale batch and a dose-range finding toxicology study, and added cancer cachexia as a new pipeline indication. The filing reports no revenue or earnings figures, and shareholders would note that cash and cash equivalents were approximately $4.0 million as of March 31, 2026.
Planned IND submission to the FDA for ulcerative colitis targeted for the fourth quarter of 2026
GMP-compliant pilot-scale batch of Phyto-N completed in February 2026; 28-day toxicology study in rats and dogs completed in March 2026
Cancer cachexia added as a new core indication after quarter-end; cited market estimate of approximately $2.54 billion in 2024
Cash and cash equivalents of approximately $4.0 million as of March 31, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Curanex Pharmaceuticals Inc filing is on SEC EDGAR ↗. 8-K briefs of other companies →